REOLYSIN® Addressable Market

We have clinical trials underway for a wide variety of cancer indications, including:


Pancreatic Cancer

GLOBOCAN estimates that, in 2012, 337,872 patients worldwide were diagnosed with pancreatic cancer, and 330,391 died as a result of the disease. According to the American Cancer Society, the prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 6%.

View Studies

Breast Cancer

GLOBOCAN estimates that, in 2012, 1,671,149 women worldwide were diagnosed with breast cancer, and 189,382 lost their lives as a result of the disease.

View Studies

Lung Cancer

GLOBOCAN estimates that, in 2012, 1,824,701 new cases of lung cancer were diagnosed worldwide, and 1,589,925 patients lost their lives as a result of the disease. According to the American Cancer Society, approximately 85% of all lung cancers are classified as non-small cell lung cancer (NSCLC); squamous cell carcinomas account for 25-30% of all lung cancers. Lung cancer is by far the leading cause of cancer death among both men and women. There were an estimated 159,000 deaths from lung cancer in 2009, accounting for around 28% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined.

View Studies

Multiple Myeloma

GLOBOCAN estimates that, in 2012, 114,251 patients worldwide were diagnosed with multiple myeloma, and 80,019 lost their lives as a result of the disease. According to the American Cancer Society, the prognosis for patients diagnosed with multiple myeloma varies but the five-year survival rate for the period between 1999 and 2005 was approximately 37%.

View Studies

Colorectal Cancer

GLOBOCAN estimates that, in 2012, 1,360,602 patients worldwide were diagnosed with colorectal cancer, and 521,907 died as a result of the disease.

View Studies

Glioma

According to the International Agency for Research on Cancer’s GLOBOCAN Project (GLOBOCAN), in 2012, 256,213 patients worldwide were diagnosed with gliomas and 189,382 patients died as a result of the disease.
The Central Brain Tumor Registry of the United States (CBTRUS) notes that the median survival for patients with glioblastoma multiforme (GBM), the most common type of malignant glioma, is around one year. Gliomas also represent approximately 80% of malignant tumors in patients between zero and 19 years of age, with an estimated 4,620 new cases diagnosed in pediatric and adolescent patients in 2015 in the United States alone.

View Studies

Prostate Cancer

Cancer of the prostate is one of the most common cancers in men, representing approximately one-third of all male cancers in western countries. It is second only to lung cancer as the leading cause of cancer deaths in men. GLOBOCAN estimates that 1,094,916 men worldwide were diagnosed with prostate cancer in 2012, and that 307,481 died as a result of the disease.

View Studies

Ovarian Cancer

According to GLOBOCAN, in 2012, 238,719 women worldwide were diagnosed with ovarian cancer, and 151,917 died as a result of the disease. The American Cancer Society notes that ovarian cancer accounts for about 5% of all cancer deaths in women. The prognosis for patients diagnosed with ovarian cancer at the localized stage is good, with a five-year survival rate of 92%; however, only about 15% of cases are diagnosed at this stage. The relative 10-year survival rate for all stages combined is approximately 35%.

View Studies

The US Food and Drug Administration (FDA) has granted us Orphan Drug Designations for REOLYSIN® for malignant gliomas and ovarian, primary peritoneal, fallopian tube, pancreatic and gastric cancers. We have also received Orphan Drug Status from the European Medicines Agency (EMA) for REOLYSIN® for ovarian and pancreatic cancers.